CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide

International Journal of Cancer

Volumn 127, Issue 9, 2010, Pages 2020-2030

  Sharma, Praveen K ^a   Singh, Rajesh ^a,c   Novakovic, Kristian R ^a   Eaton, John W ^a   Grizzle, William E ^b   Singh, Shailesh ^a  

^a University of Louisville School of Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; CCR9 CCL25; chemokine; etoposide; PI3K AKT

Indexed keywords

CASPASE 3; CHEMOKINE; CHEMOKINE CCL25; CHEMOKINE CCL25 ANTIBODY; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CCR9 MONOCLONAL ANTIBODY; ETOPOSIDE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; WORTMANNIN; ANTINEOPLASTIC AGENT; BETA CHEMOKINE; CC CHEMOKINE RECEPTOR 9; CCL25 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; DISEASE COURSE; HUMAN; METABOLISM; NUDE MOUSE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CHEMOKINES, CC; DISEASE PROGRESSION; ENZYME ACTIVATION; ETOPOSIDE; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CCR; SIGNAL TRANSDUCTION;

EID: 77956633638     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25219     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225 -49.
2. Oh WK, Kantoff PW,. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160: 1220 -9.
3. Denmeade SR, Isaacs JT,. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 1996; 35: 281 -306.
4. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E,. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995; 55: 2122 -8.
5. Khan MZ, Brandimarti R, Shimizu S, Nicolai J, Crowe E, Meucci O,. The chemokine CXCL12 promotes survival of postmitotic neurons by regulating Rb protein. Cell Death Differ 2008; 15: 1663 -72.
6. Ticchioni M, Essafi M, Jeandel PY, Davi F, Cassuto JP, Deckert M, Bernard A,. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 2007; 26: 7081 -91.
7. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20: 318 -29.
8. Singh S, Singh UP, Grizzle WE, Lillard JW,. CXCL12-CXCR4 interactions modulates prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004; 84: 1666 -76.
9. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW,. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res 2004; 10: 8743 -50.
10. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS,. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003; 89: 462 -73.
11. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK,. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832 -7.
12. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50 -6.
13. Reiland J, Furcht LT, McCarthy JB,. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999; 41: 78 -88.
14. Ward SG, Bacon K, Westwick J,. Chemokines and T lymphocytes: more than an attraction. Immunity 1998; 9: 1 -11.
15. Wang JM, Deng X, Gong W, Su S,. Chemokine and their role in tumor growth and metastasis. J Immunol Methods 1998; 220: 1 -17.
16. Roh KJ, Kim DJ, Kim DW, Wang JM,. Chemokines and their role in tumor growth and metastasis. J Bone Joint Surg Br 1998; 80: 1005 -8.
17. Keane MP, Arenberg DA, Moore BB, Addison CL, Strieter RM,. CXC chemokines and angiogenesis/angiostasis. Proc Assoc Am Physicians 1998; 110: 288 -96.
18. Shailesh S, Rajesh S, Udai PS, Shesh NR, Kristian RN, Leland WKC, Peter JD, William EG, James WL, Jr,. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer 2009; 125: 2288 -95.
19. Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E, Scheibenbogen C,. Functional CCR9 expression is associated with small intestinal metastasis.[see comment]. J Invest Dermatol 2004; 122: 685 -90.
20. Amersi FF, Terando AM, Goto Y, Scolyer RA, Thompson JF, Tran AN, Faries MB, Morton DL, Hoon DS,. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 2008; 14: 638 -45.
21. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, Agace W,. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 2003; 198: 963 -9.
22. Youn BS, Kim CH, Smith FO, Broxmeyer HE,. TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCR9 as a specific receptor. Blood 1999; 94: 2533 -6.
23. Zaballos A, Gutierrez J, Varona R, Ardavin C, Marquez G,. Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 1999; 162: 5671 -5.
24. Yu CR, Peden KW, Zaitseva MB, Golding H, Farber JM,. CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck -15 that differ in their sensitivities to ligand. J Immunol 2000; 164: 1293 -305.
25. Datta SR, Brunet A, Greenberg ME,. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905 -27.
26. Jenkins DE, Yu SF, Purchio T, Contag PR,. In vivo monitering of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine model of prostate cancer. Clin Exp Metastasis 2003; 20: 745 -56.
27. Scatena CD, Hepner MA, Oei YA, Dusich JM, Yu SF, Purchio T, Contag PR, Jenkins DE,. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate 2004; 59: 292 -303.
28. Fuchs J, Wenderoth M, von Schweinitz D, Haindl J, Leuschner I,. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 1998; 83: 2400 -7.
29. Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, Poupon MF,. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Clin Cancer Res 2000; 6: 2075 -86.
30. Tanimoto C, Hirakawa S, Kawasaki H, Hayakawa N, Ota Z,. ICRF-193 modifies etoposide-induced apoptosis in thymocytes. Acta Med Okayama 1995; 49: 281 -6.
31. Chen G, Shu J, Stacey DW,. Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide. Oncogene 1997; 15: 1643 -51.
32. Kamradt JM, Pienta KJ,. Etoposide in prostate cancer. Expert Opin Pharmacother 2000; 1: 271 -5.
33. Baldwin EL, Osheroff N,. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005; 5: 363 -72.
34. Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Muller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A,. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 2007; 109: 1543 -9.
35. Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ,. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 2003; 98: 269 -76.
36. Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y,. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J 1997; 16: 2271 -81.
37. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502 -12.
38. Kerr JF, Wyllie AH, Currie AR,. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239 -57.
39. Lean JM, Murphy C, Fuller K, Chambers TJ,. CCL9/MIP-1γ and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem 2002; 87: 386 -93.
40. Vicari AP, Figueroa DJ, Hendrick JA, Foster JS, Singh KP, Menon S, Copeland NG, Gilbert DJ, Jenkins NA, Bacon KB, Zlotnik A,. TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity 1997; 7: 291 -301.
41. Stich S, Loch A, Leinhase I, Neumann K, Kaps C, Sittinger M, Ringe J,. Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13. Eur J Cell Biol 2008; 87: 365 -76.
42. Amersi FF, Terando AM, Goto Y, Scolyer RA, Thompson JF, Tran AN, Faries MB, Morton DL, Hoon DS,. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 2008; 14: 638 -45.
43. Cantrell DA,. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114: 1439 -45.
44. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G,. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687 -9.
45. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME,. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231 -41.
46. Williams KM, Lucas PJ, Bare CV, Wang J, Chu YW, Tayler E, Kapoor V, Gress RE,. CCL25 increases thymopoiesis after androgen withdrawal. Blood 2008; 112: 3255 -63.
47. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P,. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393 -412.
48. Tolcher AW, Yap TA, Fearen I, Taylor A, Carpenter C, Brunetto AT, Beeram M, Papadopoulos K, Yan L, de Bono J,. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (AKti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009; 27: 15s (Suppl; abstr 3503).